- May 19, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Evista, ACT Raloxifene, APO-Raloxifene
Synonyms :
raloxifene
Class :
Anticancer & Hormonal agents
Dosage forms & Strengths
Tablet, Oral
60 mg
For postmenopausal females:
60
mg
Orally
once a day
Note: ensure adequate calcium and vitamin D intake during therapy, recommended intake of vitamin D is 400-800 IU daily
5 years of duration of therapy for postmenopausal females:
60
mg
Orally
once a day
The duration can be modified for use longer than 5 years depending on the disease progression and symptoms
Limitations of raloxifene therapy:
No specific recommendation is available for the effectiveness of raloxifene in breast cancer associated with BRCA1 and BRCA2
Not indicated for the reduction of the risk of recurrence of breast cancer
Not recommended for reduction in risk of non-invasive breast cancer
Dose Adjustments
Use with caution if creatinine clearance is <50 ml/minute
No significant data available for dose adjustment for hepatic impairment
No safe dosing is described
Refer to adult dosing
ospemifene may diminish the therapeutic effects of raloxifene or may enhance adverse toxic effects of raloxifene
It may diminish the absorption when combined with bile acid sequestrants
may enhance the concentration of serum when combined with OAT1/3 substrates
apalutamide will increase the excretion of raloxifene and decrease the therapeutic effect
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
decreases the serum level of raloxifene by inhibiting GI absorption separate bile sequestrant from raloxifene by at least 4 hours
raloxifene decreases the therapeutic effects of famciclovir by aldehyde dehydrogenase inhibition
may increase GI absorption of levothyroxine and decrease serum levels
may increase the serum concentration of OAT1/3 substrates
may result in a significant increase in zavegepant exposure
may diminish the serum concentration of each other when combined
Frequency defined:
>10%:
Leg cramps
Muscle spasm
Flu-like symptoms
Peripheral edema
Hot flash
1% to 10%
Chest pain
Neuralgia
Insomnia
Skin rash
Weight gain
Sinusitis
Laryngitis
Pneumonia
<1%
Decreased serum cholesterol
Cerebrovascular accident
Decreased LDL cholesterol
Pregnancy consideration: Raloxifene is assigned under pregnancy category X.
Lactation: No sufficient data is available about drug excretion in breast milk
Pregnancy category:
Patient information leaflet
Generic Name: raloxifene
Why do we use raloxifene?
raloxifene is a medication that is used to treat and prevent osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of developing the disease.
Osteoporosis is a condition that weakens bones, making them more likely to fracture or break. After menopause, women are at increased risk of osteoporosis due to lower levels of estrogen, which plays a key role in maintaining bone health. raloxifene works by mimicking the effects of estrogen in some tissues, which can help to maintain bone density and reduce the risk of fractures.